Bucindolol is a non-selective beta blocker with additional weak alpha-blocking properties and some intrinsic sympathomimetic activity. It was under review by the FDA in the United States for the treatment of heart failure in 2009, but was rejected due to issues pertaining to integrity of data submitted.
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||363.45 g/mol g·mol−1|
- Willette RN, Mitchell MP, Ohlstein EH, Lukas MA, Ruffolo RR (January 1998). "Evaluation of intrinsic sympathomimetic activity of bucindolol and carvedilol in rat heart". Pharmacology. 56 (1): 30–6. doi:10.1159/000028179. PMID 9467185.
- "FDA rejects bucindolol and questions trial integrity « CardioBrief".
|This antihypertensive-related article is a stub. You can help Wikipedia by expanding it.|